Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
On October 6, 2011, the . FDA approved tadalafil  to treat the signs and symptoms of benign prostatic hyperplasia (BPH). BPH is a condition in males in which the prostate gland becomes enlarged, obstructing the free flow of urine. Symptoms may include sudden urges to urinate (urgency), difficulty in starting urination (hesitancy), a weak urine stream, and more frequent urination — especially at night. The FDA has also approved tadalafil for treatment of both BPH and erectile dysfunction (ED) where the two conditions co-exist.
The approval of cabergoline has gradually decreased the use of bromocriptine (Cycloset) for the treatment of hyperprolactinemias (abnormally high levels of prolactin in the blood). Cabergoline may be more effective than bromocriptine, and it has less bothersome side effects. Additionally, bromocriptine is given multiple times per day while cabergoline has a longer half-life which allows it to be given twice weekly. Cabergoline was first approved by the US FDA for the treatment of hyperprolactinemic disorders (high levels of prolactin) on December 23, 1996.